A review of cost-effectiveness analysis: From theory to clinical practice

被引:20
作者
Goncalves Brandao, Sara Michelly [1 ]
Brunner-La Rocca, Hans-Peter [2 ]
Pedroso de Lima, Antonio Carlos [3 ]
Bocchi, Edimar Alcides [1 ]
机构
[1] Univ Sao Paulo, Inst Coracao Hosp Clin, Fac Med, Sao Paulo, Brazil
[2] Maastricht Univ, Dept Cardiol, Heart Failure Clin, Med Ctr, Maastricht, Netherlands
[3] Univ Sao Paulo, Inst Math & Stat, Dept Stat, Sao Paulo, Brazil
关键词
bootstrapping and health policy; cost-effectiveness analysis; cost-utility analysis; health economics; QALY; ECONOMIC-EVALUATION; CONFIDENCE-INTERVALS; HEALTH; UNCERTAINTY;
D O I
10.1097/MD.0000000000035614
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cost-effectiveness analysis has long been practiced; registries date back to the United States of America War Department in 1886. In addition, everyone does intuitive cost-effectiveness analyses in their daily lives. In routine medical care, health economic assessment becomes increasingly important due to progressively limited resources, rising demands, population increases, and continuous therapeutic innovations. The health economic assessment must analyze the outcomes and costs of actions and technologies as objectively as possible to guarantee efficient assessment of novel interventions for Public Health Policy. In other words, it is necessary to determine how much society or patients are willing to or able to pay for novel interventions compared with existing alternatives, given the available resources. In addition, increased cost may displace other health care services already provided in case of fixed budget health care systems. To conduct such analyses, researchers must use standard methodologies and interpretations in light of regional characteristics according to social and economic determinants as well as clinical practice. Such an approach may be essential for transforming the current healthcare system to a value-based model. In this narrative review, concepts of the importance of and some approaches to health economic evaluation in clinical practice will be discussed.
引用
收藏
页数:7
相关论文
共 48 条
[1]   Discounting in Economic Evaluations [J].
Attema, Arthur E. ;
Brouwer, Werner B. F. ;
Claxton, Karl .
PHARMACOECONOMICS, 2018, 36 (07) :745-758
[2]  
Baltussen RMPM, 2002, INT J TECHNOL ASSESS, V18, P112
[3]   Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development [J].
Bodrogi, Jozsef ;
Kalo, Zoltan .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (07) :1367-1373
[4]  
Brasil. Ministerio da Saude. Secretaria de Ciencia Tecnologia e Insumos Estrategicos, 2014, Diretrizes metodologicas: Diretriz de Avaliacao Economica
[5]   UNCERTAINTY IN THE ECONOMIC-EVALUATION OF HEALTH-CARE TECHNOLOGIES - THE ROLE OF SENSITIVITY ANALYSIS [J].
BRIGGS, A ;
SCULPHER, M ;
BUXTON, M .
HEALTH ECONOMICS, 1994, 3 (02) :95-104
[6]  
Briggs A., 2006, Decision Modelling for Health Economic Evaluation, P256
[7]  
Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO
[8]  
2-W
[9]  
Briggs AH, 1999, STAT MED, V18, P3245, DOI 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO
[10]  
2-2